Sebastian Bender

机构：Merck KGaA, Darmstadt (Germany)

发表论文 132 篇 · 总被引 13542 次 · h-index 31

代表论文

• Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study (2019 · The Lancet Oncology · 被引 181)
• Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID (2020 · Clinical Chemistry · 被引 41)
• Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression. (2020 · Journal of Clinical Oncology · 被引 6)
• Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer (2026 · Neoplasia)
• Supplementary Table S1 from The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas (2023)
• Data from The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas (2023)